RDHL ▼ -2.2% - RedHill Biopharma Ltd. $RDHL RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq® RedHill Biopharma shares fell 2.2% despite announcing a transformational acquisition of commercialization rights to Ferring's Rebyota® and Clenpiq®, suggesting investors may have concerns about the financial terms, integration challenges, or the company's ability to execute on the expanded portfolio. The decline indicates the market is weighing the long-term strategic benefits against potential near-term costs or dilution from the deal. 01-SEP-2026 07:01 AM ET